These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30058103)

  • 1. Evaluation of angiotensin II type-1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role.
    Sabbadin C; Ceccato F; Ragazzi E; Boscaro M; Betterle C; Armanini D
    J Clin Hypertens (Greenwich); 2018 Sep; 20(9):1313-1318. PubMed ID: 30058103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma.
    Rossitto G; Regolisti G; Rossi E; Negro A; Nicoli D; Casali B; Toniato A; Caroccia B; Seccia TM; Walther T; Rossi GP
    Hypertension; 2013 Feb; 61(2):526-33. PubMed ID: 23248149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT1AA (Angiotensin II Type-1 Receptor Autoantibodies): Cause or Consequence of Human Primary Aldosteronism?
    Piazza M; Seccia TM; Caroccia B; Rossitto G; Scarpa R; Persichitti P; Basso D; Rossi GP
    Hypertension; 2019 Oct; 74(4):793-799. PubMed ID: 31476908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism.
    Kem DC; Li H; Velarde-Miranda C; Liles C; Vanderlinde-Wood M; Galloway A; Khan M; Zillner C; Benbrook A; Rao V; Gomez-Sanchez CE; Cunningham MW; Yu X
    J Clin Endocrinol Metab; 2014 May; 99(5):1790-7. PubMed ID: 24552217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
    Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse Responses of Autoantibodies to the Angiotensin II Type 1 Receptor in Primary Aldosteronism.
    Williams TA; Jaquin D; Burrello J; Philippe A; Yang Y; Rank P; Nirschl N; Sturm L; Hübener C; Dragun D; Bidlingmaier M; Beuschlein F; Reincke M
    Hypertension; 2019 Oct; 74(4):784-792. PubMed ID: 31476909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of angiotensin II type 1 receptor (AT1R)-activating autoantibodies in primary aldosteronism.
    Li H; Yu X; Cicala MV; Mantero F; Benbrook A; Veitla V; Cunningham MW; Kem DC
    J Am Soc Hypertens; 2015 Jan; 9(1):15-20. PubMed ID: 25537460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II Type 1 Receptor Autoantibodies in Primary Aldosteronism.
    Meyer LS; Gong S; Reincke M; Williams TA
    Horm Metab Res; 2020 Jun; 52(6):379-385. PubMed ID: 32168525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Angiotensin II Type 1 Receptor Antibodies in Persons With Hypertension and Relation to Blood Pressure and Medication.
    Philogene MC; Han D; Alvarado F; Fedarko NS; Zonderman AB; Evans MK; Crews DC
    Am J Hypertens; 2020 Aug; 33(8):734-740. PubMed ID: 32330222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of risk factors for post-treatment renal dysfunction between the two major subtypes of primary aldosteronism.
    Watanabe D; Morimoto S; Morishima N; Ichihara A
    Endocrine; 2024 Apr; 84(1):245-252. PubMed ID: 38087188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-nephrectomy angiotensin II type 1 receptor antibodies in living kidney donors: A concern?
    Hernández-Méndez EA; Arreola-Guerra JM; Morales-Buenrostro LE; Ramírez JB; Calleja S; Castelán N; Salcedo I; Vilatobá M; Contreras AG; Gabilondo B; Granados J; Alberú J
    Clin Transpl; 2013; ():351-5. PubMed ID: 25095528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
    Morimoto S; Ichihara A
    Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the medical treatment of primary aldosteronism.
    Lim PO; Young WF; MacDonald TM
    J Hypertens; 2001 Mar; 19(3):353-61. PubMed ID: 11288803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differences of blood plasma renin activity, angiotensin II and aldosterone levels in essential or secondary hypertension].
    Song AL; Zeng ZP; Tong AL; Lu L; Chen S; Li M; Fu CL; Wang YH; Sun ML
    Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):294-8. PubMed ID: 22781950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nocturnal, daytime, and postural changes of plasma aldosterone before and during dexamethasone in adenomatous and idiopathic aldosteronism.
    Hoefnagels WH; Drayer JI; Smals AG; Benraad TJ; Kloppenborg PW
    J Clin Endocrinol Metab; 1980 Dec; 51(6):1330-4. PubMed ID: 7440698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
    Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worsening of lipid metabolism after successful treatment of primary aldosteronism.
    Adolf C; Asbach E; Dietz AS; Lang K; Hahner S; Quinkler M; Rump LC; Bidlingmaier M; Treitl M; Ladurner R; Beuschlein F; Reincke M
    Endocrine; 2016 Oct; 54(1):198-205. PubMed ID: 27179655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design.
    Rossitto G; Cesari M; Ceolotto G; Maiolino G; Seccia TM; Rossi GP
    J Hum Hypertens; 2019 Feb; 33(2):167-171. PubMed ID: 30518805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.